AutoPhagyGO Anti-Aging Medical Society Announces Human Clinical Trial Results at Global Competition XPRIZE HEALTHSPAN Aiming for '10-Year Rejuvenation'

AutoPhagyGO Inc. (Headquarters: Suita City, Osaka Prefecture; President and CEO: Miwako Ishido; hereinafter 'AutoPhagyGO') announced the results of the XPRIZE HEALTHSPAN semifinal trial at the 26th Annual Meeting of the Japanese Society of Anti-Aging Medicine held on June 27, 2026.

In this study, an 8-week multifaceted intervention combining nutrition, exercise, and sleep targeting autophagy activation was conducted on healthy middle-aged and older adults. The results showed favorable changes in multiple healthspan-related indicators, as well as findings suggesting the utility of human autophagy activity assessment—a method not yet established globally.

AutoPhagyGO is currently advancing research and development as one of the 'Top 40' teams selected from global applicants in the international competition 'XPRIZE HEALTHSPAN'.

[Key Points of the Presentation]

An 8-week intervention trial comprehensively evaluating healthspan in healthy middle-aged and older adults

An 8-week program combining autophagy-activating supplements, dietary management, exercise, and sleep management was conducted on healthy individuals aged 50–80, with assessments of physical function, cognitive function, immune function, and other parameters.

Favorable changes observed in healthspan-related indicators

The 8-week autophagy program was safely implemented with high adherence, resulting in favorable changes in multiple healthspan-related indicators including lower-limb muscle function, muscle quality, cognitive function, fatigue, and sleep. No significant safety concerns were observed.

Accumulation of insights toward practical human autophagy activity assessment

Results suggestive of autophagy activation were obtained, including increased platelet LC3-II flux and decreased serum and urinary Rubicon levels. Quantitative evaluation of autophagy in humans has not yet been established globally, and this study contributes foundational insights toward its practical application. However, this trial was a small-scale exploratory study, and further validation is required.

※For detailed materials related to this presentation, please contact the public relations representative.

[Official Comment]

Extending healthspan is a shared societal challenge worldwide.

AutoPhagyGO focuses on autophagy—a key mechanism in aging research—and is advancing research and development toward its real-world implementation.

This presentation reports the outcomes of an exploratory study conducted as part of the XPRIZE HEALTHSPAN semifinal. While positive results were observed in muscle and cognitive functions, significant challenges remain in making autophagy assessment practical.

We will continue striving to accumulate scientific evidence and contribute to extending healthspan through collaboration with research institutions and medical professionals, including Osaka University.

Miwako Ishido, President and CEO, AutoPhagyGO Inc.

About 'AutoPhagyGO'

AutoPhagyGO is a venture company originating from Osaka University, promoting the real-world application of autophagy based on the research of Professor Yasuo Mizushima (Professor Emeritus, Osaka University), a leading expert in autophagy research.

Autophagy is a cellular mechanism that continuously breaks down and replaces cellular components to maintain cellular health. It has recently gained significant attention as a crucial process for extending healthspan and preventing age-related diseases.

The company has currently been selected as a semifinalist (Top 40 globally) in the international competition 'XPRIZE HEALTHSPAN'.

Future Outlook

AutoPhagyGO will continue leveraging advances in autophagy research to develop products that contribute to extending healthspan. The company also aims to accelerate the real-world implementation of autophagy through collaborative research with corporations and research institutions.

Company Overview

AutoPhagyGO Inc.

A406, Co-Creation Building A, Osaka University, 2-1 Yamadaka, Suita City, Osaka 565-0871, Japan

Official Website: https://autophagygo.com/

Contact

AutoPhagyGO Inc.

Product Inquiries: Mizutani

Email: cs@autophagygo.com

Public Relations: Ochi

Email: info@autophagygo.com

※The information contained in this press release is current as of the date of announcement and is subject to change without prior notice.